End-of-day quote
INDONESIA S.E.
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
735
IDR
|
-1.34%
|
|
+0.68%
|
-49.13%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
14,995,800
|
14,440,400
|
6,942,500
|
23,604,500
|
13,496,220
|
6,026,090
|
Enterprise Value (EV)
1 |
16,025,672
|
16,519,990
|
13,878,890
|
30,115,451
|
20,771,679
|
11,986,304
|
P/E ratio
|
45.9
x
|
34.7
x
|
-546
x
|
1,338
x
|
44.6
x
|
-35.4
x
|
Yield
|
-
|
-
|
-
|
0.03%
|
-
|
-
|
Capitalization / Revenue
|
2.45
x
|
1.94
x
|
0.74
x
|
2.36
x
|
1.05
x
|
0.63
x
|
EV / Revenue
|
2.62
x
|
2.22
x
|
1.48
x
|
3.01
x
|
1.62
x
|
1.25
x
|
EV / EBITDA
|
29.1
x
|
20.8
x
|
24.4
x
|
37.7
x
|
17.1
x
|
13.2
x
|
EV / FCF
|
-18.5
x
|
-16.1
x
|
-5.61
x
|
34.9
x
|
-17.8
x
|
-22
x
|
FCF Yield
|
-5.41%
|
-6.2%
|
-17.8%
|
2.86%
|
-5.62%
|
-4.54%
|
Price to Book
|
5.97
x
|
4.51
x
|
0.96
x
|
3.38
x
|
1.89
x
|
0.76
x
|
Nbr of stocks (in thousands)
|
5,554,000
|
5,554,000
|
5,554,000
|
5,554,000
|
5,554,000
|
5,554,000
|
Reference price
2 |
2,700
|
2,600
|
1,250
|
4,250
|
2,430
|
1,085
|
Announcement Date
|
3/28/18
|
4/2/19
|
3/27/20
|
3/31/21
|
3/31/22
|
4/1/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
6,127,479
|
7,454,115
|
9,400,535
|
10,006,173
|
12,857,627
|
9,606,145
|
EBITDA
1 |
550,139
|
795,157
|
567,697
|
799,644
|
1,214,604
|
908,821
|
EBIT
1 |
486,400
|
692,137
|
410,181
|
636,298
|
969,247
|
534,638
|
Operating Margin
|
7.94%
|
9.29%
|
4.36%
|
6.36%
|
7.54%
|
5.57%
|
Earnings before Tax (EBT)
1 |
449,710
|
577,726
|
38,315
|
73,359
|
392,883
|
49,622
|
Net income
1 |
326,786
|
415,896
|
-12,724
|
17,639
|
302,274
|
-170,045
|
Net margin
|
5.33%
|
5.58%
|
-0.14%
|
0.18%
|
2.35%
|
-1.77%
|
EPS
2 |
58.84
|
74.88
|
-2.291
|
3.176
|
54.42
|
-30.62
|
Free Cash Flow
1 |
-867,144
|
-1,024,930
|
-2,472,297
|
861,885
|
-1,167,329
|
-543,663
|
FCF margin
|
-14.15%
|
-13.75%
|
-26.3%
|
8.61%
|
-9.08%
|
-5.66%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
107.78%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
4,886.29%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
1.270
|
-
|
-
|
Announcement Date
|
3/28/18
|
4/2/19
|
3/27/20
|
3/31/21
|
3/31/22
|
4/1/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
1,029,872
|
2,079,590
|
6,936,390
|
6,510,951
|
7,275,459
|
5,960,214
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.872
x
|
2.615
x
|
12.22
x
|
8.142
x
|
5.99
x
|
6.558
x
|
Free Cash Flow
1 |
-867,144
|
-1,024,930
|
-2,472,297
|
861,885
|
-1,167,329
|
-543,663
|
ROE (net income / shareholders' equity)
|
13.7%
|
13.6%
|
0.27%
|
0.28%
|
4.04%
|
-1.14%
|
ROA (Net income/ Total Assets)
|
5.68%
|
5.56%
|
1.73%
|
2.21%
|
3.43%
|
1.75%
|
Assets
1 |
5,755,711
|
7,478,257
|
-736,641
|
796,515
|
8,812,899
|
-9,698,023
|
Book Value Per Share
2 |
452.0
|
577.0
|
1,304
|
1,259
|
1,285
|
1,435
|
Cash Flow per Share
2 |
178.0
|
353.0
|
245.0
|
225.0
|
135.0
|
388.0
|
Capex
1 |
751,823
|
1,010,690
|
774,407
|
544,486
|
650,761
|
593,351
|
Capex / Sales
|
12.27%
|
13.56%
|
8.24%
|
5.44%
|
5.06%
|
6.18%
|
Announcement Date
|
3/28/18
|
4/2/19
|
3/27/20
|
3/31/21
|
3/31/22
|
4/1/23
|
|
1st Jan change
|
Capi.
|
---|
| -49.13% | 252M | | -32.21% | 15.27B | | -31.97% | 10.84B | | -30.42% | 6.06B | | +8.14% | 6.04B | | -11.41% | 5.86B | | -0.88% | 4.71B | | +52.19% | 4.29B | | -12.31% | 3.61B | | -14.86% | 3.33B |
Other Drug Retailers
|